OVERVIEW
Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally perianally to treat fecal incontinence. A number of products have been developed; the U.S. Food and Drug Administration (FDA) has approved 1 for treating fecal incontinence.

MEDICAL CRITERIA
Not applicable.

PRIOR AUTHORIZATION
Not applicable.

POLICY STATEMENT
This policy is applicable to Commercial Products only. For Blue CHiP for Medicare, see related policy section. Injectable bulking agents in the treatment of fecal incontinence are considered not medically necessary as there is insufficient evidence in published peer reviewed medical literature to support their use.

COVERAGE
Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for limitations of benefits/coverage when services are not medically necessary.

BACKGROUND
Bulking agents injected into the anal canal have been proposed for treating fecal incontinence. In particular, bulking agents are a potential treatment for passive fecal incontinence associated with internal anal sphincter dysfunction. The bulking agent is injected into the submucosa of the anal canal to increase tissue bulk in the area, which narrows the opening of the anus. Current treatment options for fecal incontinence include conservative measures eg, dietary changes, pharmacotherapy and pelvic floor muscle exercises, sacral nerve stimulation, and surgical interventions to correct an underlying problem.

Several agents have been studied for the treatment of fecal incontinence. To date, only 1 bulking agent has been approved by FDA for treating fecal incontinence. This is a formulation of nonanimal stabilized hyaluronic acid/dextranomer in stabilized hyaluronic acid (NASHA Dx) and is marketed by Q-Med as Solesta.

Overall, the evidence is not sufficient to conclude whether bulking agents are an effective treatment for fecal incontinence. Therefore, injectable bulking agents in the treatment of fecal incontinence are not medically necessary due to insufficient evidence in published peer reviewed medical literature to support its use.

CODING
Commercial Products
The following codes are not medically necessary:
0377T  Anoscopy with directed submucosal injection of bulking agent for fecal incontinence (Effective January 1, 2015)
L8605  Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal
RELATED POLICIES
BlueCHiP for Medicare National and Local Coverage Determinations Policy

PUBLISHED
Provider Update, January 2017
Provider Update Dec 2015
Provider Update, July 2014
Policy Update, April 2013

REFERENCES:

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.